keyword
MENU ▼
Read by QxMD icon Read
search

conbercept

keyword
https://www.readbyqxmd.com/read/28980574/-anti-vegf-therapy-resistance-in-neovascular-age-related-macular-degeneration
#1
M V Budzinskaya, A A Plyukhova, P A Sorokin
With account to the increase in the elderly population in most of the developed countries, the WHO defines age-related macular degeneration (AMD) as one of the main causes of blindness in the world. A large percentage of disability is accounted for by exudative, or neovascular, form of AMD. Today, a total of 5 anti-VEGF drugs exist that are recommended for treatment of exudative AMD: pegaptanib, ranibizumab, bevacizumab, aflibercept, and conbercept. Despite significant progress in the treatment of neovascular AMD yielded by the introduction into clinical practice of anti-VEGF drugs, some patients report a lack (down to complete lack) of response with standard treatment patterns and even a decrease in treatment efficacy after repeated intravitreal injections...
2017: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/28937147/comparison-of-effectiveness-and-safety-between-conbercept-and-ranibizumab-for-treatment-of-neovascular-age-related-macular-degeneration-a-retrospective-case-controlled-non-inferiority-multiple-center-study
#2
J Cui, D Sun, H Lu, R Dai, L Xing, H Dong, L Wang, D Wei, B Jiang, Y Jiao, M M Jablonski, S Charles, W Gu, H Chen
PurposeTo compare the efficacy and safety of conbercept and ranibizumab when administered according to a treat-and-extend (TREX) protocol for the treatment of neovascular age-related macular degeneration (AMD) in China.Patients and methodsBetween May 2014 and May 2015, 180 patients were treated in a 1 : 1 ratio using conbercept or ranibizumab from four hospitals. Patients received either conbercept 0.5 mg or ranibizumab 0.5 mg intravitreal injections. Follow-up time was 1 year and treated based on a TREX approach...
September 22, 2017: Eye
https://www.readbyqxmd.com/read/28841827/comparison-of-12-month-therapeutic-effect-of-conbercept-and-ranibizumab-for-diabetic-macular-edema-a-real-life-clinical-practice-study
#3
Yule Xu, Ao Rong, Wei Xu, Yunli Niu, Zhen Wang
BACKGROUND: To compare the efficacy of intravitreal conbercept and ranibizumab in the treatment of diabetic macular edema (DME) in a real-life clinical practice. METHODS: This was a retrospective study. Among 62 Chinese patients with DME, 32 patients (36 eyes) received intravitreal conbercept (IVC) injections and 30 patients (32 eyes) received intravitreal ranibizumab (IVR) injections, once a month for 3 months followed by as needed therapy. All participants had at least 12 months of follow-up...
August 25, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28730115/diabetic-macular-edema-in-proliferative-stage-treated-with-anti-vascular-endothelial-growth-factor-agent-and-triamcinolone-acetonide-by-laser-based-strategies
#4
Gang Qiao, Wan-Jiang Dong, Yan Dai, Zhen-Hua Jiang, Hai-Ke Guo
AIM: To appraise the effect of treatment for diabetic macular edema (DME) in proliferative stage with sufficient panrentinal photocoagulation (PRP) therapy and intravitreal injections (IV) Conbercept and posterior subtenon's triamcinolone acetonide (STTA) sequential therapy. METHODS: This prospective clinical randomized controlled trial of cross-over design was conducted in three phases. The participants included cases of DME in proliferative stage. They were divided into two groups and treated with PRP before enrollment...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28699927/short-term-outcomes-after-intravitreal-injections-of-conbercept-versus-ranibizumab-for-the-treatment-of-retinopathy-of-prematurity
#5
Enzhong Jin, Hong Yin, Xiaoxin Li, Mingwei Zhao
PURPOSE: Intravitreal injection of conbercept (IVC) is the latest applied treatment that could be used in retinopathy of prematurity (ROP) patients. The structural outcomes and recurrence of ROP among patients treated with IVC or intravitreal injection of ranibizumab (IVR) were compared. METHODS: A consecutive case series of ROP treated with IVC or IVR were retrospectively studied. The primary outcome was treatment success defined as regression of plus disease. The secondary outcomes were recurrence of plus, times of injection, and the final regression of disease...
July 7, 2017: Retina
https://www.readbyqxmd.com/read/28606070/efficacy-and-safety-of-conbercept-as-a-primary-treatment-for-choroidal-neovascularization-secondary-to-punctate-inner-choroidopathy
#6
Yuting Peng, Xiongze Zhang, Lan Mi, Bing Liu, Chengguo Zuo, Miaoling Li, Feng Wen
BACKGROUND: To evaluate the efficacy and safety of intravitreal conbercept (KH902) as the primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy. METHODS: This study was a retrospective, consecutive, observational case series. We reviewed medical records of 16 eyes (16 patients) with naive subfoveal or juxtafoveal choroidal neovascularization secondary to punctuate inner choroidopathy that were treated with intravitreal conbercept injections...
June 12, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28441077/comparison-of-conbercept-with-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-branch-retinal-vein-occlusion
#7
Fengjiao Li, Ming Sun, Jianlian Guo, Aihua Ma, Bojun Zhao
PURPOSE: To confirm the therapeutic efficacy of conbercept for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS: In this prospective, randomized, and comparative study, patients were randomized and divided into conbercept (n = 18) and ranibizumab (n = 17) groups. After an initial intravitreal injection of either conbercept or ranibizumab, a pro re nata (PRN) strategy was adopted based on loss of visual acuity (VA) or increase in central macular thickness (CMT)...
August 2017: Current Eye Research
https://www.readbyqxmd.com/read/28420611/characterization-of-the-conbercept-gene-localization-in-dhfr-amplified-cho-cells-using-fluorescence-in-situ-hybridization
#8
Ming-lei Shi, Wei-li Lai, Tian-hong Yi, Xiao Ke, Zhi-hu Zhao
Chinese-hamster ovary (CHO) cells are most widely used for mammalian protein expression. After integration into the CHO genome, the exogenous gene may be lost in the process of large-scale protein production due to the removal of related selection pressures. Therefore, it is necessary to test its stability in the genome. Conbercept is a fusion protein that specifically binds to the various isoforms of vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF), thereby exerting anti-angiogenic activities...
April 20, 2017: Yi Chuan, Hereditas
https://www.readbyqxmd.com/read/28377591/a-safety-study-of-high-concentration-and-high-frequency-intravitreal-injection-of-conbercept-in-rabbits
#9
Jiaming Wang, Chunyan Lei, Lifei Tao, Quan Wu, Xiao Ke, Yiguo Qiu, Bo Lei
The novel anti-VEGF drug conbercept has been used in the treatment of several retinal neovascular diseases. Owning to the alteration of the structure, the newest drug is capable of combining more molecular targets and present higher affinity to the angiogenesis promoting factors. However, it is unknown whether it will cause any unwanted effects like other anti-VEGF agents. We studied the short-term safety of high concentration and high frequency intravitreal injection of conbercept in rabbits. Intraocular pressure, fundus-photography, ERGs were applied...
April 4, 2017: Scientific Reports
https://www.readbyqxmd.com/read/27958226/correlation-of-vascular-endothelial-growth-factor-production-with-photochemical-reaction-induced-retinal-edema
#10
Liang Shan, Mi Zheng, Yuan Zhang, Yuan Qu, Tian Niu, Qing Gu, Kun Liu, Xin Xia
BACKGROUND: Retinal edema is the major complication of retinal vein occlusion and diabetic retinopathy; it can damage visual function by influencing macular region. This study was to establish a rat retinal edema model and explore the related VEGF expression and observe the responses to anti-VEGF drugs in this model. METHODS: A rat retinal edema model was established by inducing photochemical reaction using a 532 nm laser after the intravenous injection of Erythrosin B...
December 20, 2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27922068/changes-in-retinal-nerve-fiber-layer-thickness-after-multiple-injections-of-novel-vegf-decoy-receptor-conbercept-for-various-retinal-diseases
#11
Zhihua Zhang, Xiaolu Yang, Huiyi Jin, Yuan Qu, Yuan Zhang, Kun Liu, Xun Xu
Conbercept is a recombinant fusion protein with high affinity for all vascular endothelial growth factor isoforms and placental growth factor. The repeated intravitreal injection of conbercept may cause intraocular pressure (IOP) fluctuations and long-term suppression of neurotrophic cytokines, which could lead to retinal nerve fiber layer (RNFL) damage. This retrospective fellow-eye controlled study included 98 eyes of 49 patients. The changes in IOP and RNFL thickness as well as the correlation between RNFL changes and associated factors were evaluated...
December 6, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27893623/efficacy-and-safety-of-intravitreal-conbercept-injections-in-macular-edema-secondary-to-retinal-vein-occlusion
#12
Zuhua Sun, Haiying Zhou, Bing Lin, Xuan Jiao, Yingdong Luo, Feng Zhang, Shanshan Tao, Quan Wu, Zunhong Ke, Xiaoling Liu
PURPOSE: To assess the efficacy and safety of intravitreal conbercept injections in patients with macular edema secondary to retinal vein occlusion (RVO). METHODS: A prospective, Phase II clinical trial was performed on 60 patients with macular edema secondary to RVO. Thirty patients had branch RVO (BRVO) and 30 had central RVO (CRVO). Each patient received intravitreal injections of conbercept monthly up to 3 months, followed by monthly evaluation and injection pro re nata to Month 9...
September 2017: Retina
https://www.readbyqxmd.com/read/27877088/aloe-emodin-suppresses-hypoxia-induced-retinal-angiogenesis-via-inhibition-of-hif-1%C3%AE-vegf-pathway
#13
Jianming Wu, Xiao Ke, Wei Wang, Hongcheng Zhang, Na Ma, Wei Fu, Manxi Zhao, Xiaoping Gao, Xiaofeng Hao, Zhirong Zhang
Background: Aloe-emodin (AE) has been reported to possess the antiangiogenic effect on laser induced choroidal neovascularization. AE inhibits the vessel formation in the zebrafish embryos. However, it is still unclear whether AE can alleviate neovascularization. Here, we investigated the inhibitory effect of AE on the hypoxia-induced retinal neovascularization and the possible mechanisms. Methods: We established a vascular endothelial growth factor (VEGF) secretion model under chemical induced hypoxia by exposure of 150 µM CoCl2 to the ARPE-19 cells, then treated the cells with different concentrations of AE (0...
2016: International Journal of Biological Sciences
https://www.readbyqxmd.com/read/27847621/fusion-proteins-for-treatment-of-retinal-diseases-aflibercept-ziv-aflibercept-and-conbercept
#14
REVIEW
João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Eduardo Amorim Novais, Michel Eid Farah, Eduardo Büchele Rodrigues
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences. In addition to commercially available aflibercept, two other drugs, ziv-aflibercept and conbercept, have been studied in antiangiogenic treatment of ocular diseases. In this scenario, a critical review of the currently available data regarding fusion proteins in ophthalmic diseases may be a timely and important contribution...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27779169/comparison-of-the-1-year-outcomes-of-conbercept-therapy-between-two-different-angiographic-subtypes-of-polypoidal-choroidal-vasculopathy
#15
Yong Cheng, Xuan Shi, Jin-Feng Qu, Ming-Wei Zhao, Xiao-Xin Li
BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is characterized by the presence of polyps with or without a branching vascular network and more prevalent among Asians. The aim of this study was to compare the outcomes of conbercept therapy between two different angiographic subtypes of PCV. METHODS: Fifty-eight patients of PCV were classified into two phenotypes according to indocyanine green angiography (ICGA). In Type 1, both feeder and draining vessels are visible on ICGA and network vessels are numerous...
November 5, 2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27777791/intravitreal-conbercept-injection-with-and-without-grid-laser-photocoagulation-in-the-treatment-of-diffuse-diabetic-macular-edema-in-real-life-clinical-practice
#16
Yule Xu, Ao Rong, Yanlong Bi, Wei Xu
Purpose. To evaluate the efficacy of intravitreal conbercept (IVC) plus modified grid laser photocoagulation (MGP) versus IVC alone for treatment of diffuse diabetic macular edema (DDME). Methods. In this retrospective study, 51 DDME patients were treated with either IVC alone (IVC group) or IVC plus MGP (combined group) with 12 months of follow-up. The clinical records of those patients were reviewed. Results. 26 patients (31 eyes) received IVC alone and 25 patients (30 eyes) received combined therapy. At month 12, the mean best-corrected visual acuity (BCVA) letter score improvement was 9...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/27729769/formononetin-an-active-compound-of-astragalus-membranaceus-fisch-bunge-inhibits-hypoxia-induced-retinal-neovascularization-via-the-hif-1%C3%AE-vegf-signaling-pathway
#17
Jianming Wu, Xiao Ke, Na Ma, Wei Wang, Wei Fu, Hongcheng Zhang, Manxi Zhao, Xiaoping Gao, Xiaofeng Hao, Zhirong Zhang
BACKGROUND: It has been reported that formononetin (FMN), one of the main ingredients from famous traditional Chinese medicine "Huang-qi" (Astragalus membranaceus [Fisch] Bunge) for Qi-tonifying, exhibits the effects of immunomodulation and tumor growth inhibition via antiangiogenesis. Furthermore, A. membranaceus may alleviate the retinal neovascularization (NV) of diabetic retinopathy. However, the information of FMN on retinal NV is limited so far. In the present study, we investigated the effects of FMN on the hypoxia-induced retinal NV and the possible related mechanisms...
2016: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/27617537/serum-levels-of-vascular-endothelial-growth-factor-before-and-after-intravitreal-injection-of-ranibizumab-or-conbercept-for-neovascular-age-related-macular-degeneration
#18
Enzhong Jin, Yujing Bai, Ling Luo, Lvzhen Huang, Xuemei Zhu, Xue Ding, Huijun Qi, Mingwei Zhao
OBJECTIVE: To investigate the serum levels of vascular endothelial growth factor (VEGF) before and after intravitreal injection of conbercept or ranibizumab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy patients. METHODS: This study is a prospective, interventional case series and involved 28 patients, 18 treated with 0.5 mg of conbercept and 10 treated with 0.5 mg of ranibizumab. Serum concentrations of VEGF were determined by enzyme-linked immunosorbent assay before the injection and at 1 day, 1 week, and 1 month after anti-VEGF treatments...
May 2017: Retina
https://www.readbyqxmd.com/read/27514451/analysis-and-quality-control-of-carbohydrates-in-therapeutic-proteins-with-fluorescence-hplc
#19
Kun Liu, Jian Huang, Delun Luo, Kai Xu, Zhigang Wu, Xun Xu
Conbercept is an Fc fusion protein with very complicated carbohydrate profiles which must be carefully monitored through manufacturing process. Here, we introduce an optimized fluorescence derivatization high-performance liquid chromatographic method for glycan mapping in conbercept. Compared with conventional glycan analysis method, this method has much better resolution and higher reproducibility making it excellent for product quality control.
September 16, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27034822/a-randomized-controlled-trial-of-conbercept-pretreatment-before-vitrectomy-in-proliferative-diabetic-retinopathy
#20
Xiaochun Yang, Jianbiao Xu, Ruili Wang, Yan Mei, Huo Lei, Jun Liu, Ting Zhang, Haiyan Zhao
Purpose. To determine the efficacy and safety of preoperative intravitreal conbercept (IVC) injection before vitrectomy for proliferative diabetic retinopathy (PDR). Methods. 107 eyes of 88 patients that underwent pars plana vitrectomy (PPV) for active PDR were enrolled. All patients were assigned randomly to either preoperative IVC group or control group. Follow-up examinations were performed for three months after surgery. The primary bioactivity measures were severity of intraoperative bleeding, incidence of early and late recurrent VH, vitreous clear-up time, and best-corrected visual acuity (BCVA) levels...
2016: Journal of Ophthalmology
keyword
keyword
81384
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"